NCT04169737View on ClinicalTrials.gov

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

July 9, 2026

Study Completion Date

July 9, 2026

Conditions
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Interventions
DRUG

Acalabrutinib

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

AstraZeneca

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER